![Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial - The Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial - The](https://www.thelancet.com/cms/attachment/2f676c7f-ef2a-419c-b691-10a4ec006e5c/gr1.gif)
Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial - The
![Efficacy and safety of different doses of cytarabine in consolidation therapy for adult acute myeloid leukemia patients: a network meta-analysis | Scientific Reports Efficacy and safety of different doses of cytarabine in consolidation therapy for adult acute myeloid leukemia patients: a network meta-analysis | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-017-10368-0/MediaObjects/41598_2017_10368_Fig1_HTML.jpg)
Efficacy and safety of different doses of cytarabine in consolidation therapy for adult acute myeloid leukemia patients: a network meta-analysis | Scientific Reports
![Methotrexate and cytarabine inhibit progression of human lymphoma in NOD/SCID mice carrying a mutant dihydrofolate reductase and cytidine deaminase fusion gene: Molecular Therapy Methotrexate and cytarabine inhibit progression of human lymphoma in NOD/SCID mice carrying a mutant dihydrofolate reductase and cytidine deaminase fusion gene: Molecular Therapy](https://www.cell.com/cms/attachment/c538fbe9-846d-4677-9274-35d156ac78ee/gr1.jpg)
Methotrexate and cytarabine inhibit progression of human lymphoma in NOD/SCID mice carrying a mutant dihydrofolate reductase and cytidine deaminase fusion gene: Molecular Therapy
![IJMS | Free Full-Text | Inhibitors of Chemoresistance Pathways in Combination with Ara-C to Overcome Multidrug Resistance in AML. A Mini Review IJMS | Free Full-Text | Inhibitors of Chemoresistance Pathways in Combination with Ara-C to Overcome Multidrug Resistance in AML. A Mini Review](https://www.mdpi.com/ijms/ijms-22-04955/article_deploy/html/images/ijms-22-04955-g002.png)
IJMS | Free Full-Text | Inhibitors of Chemoresistance Pathways in Combination with Ara-C to Overcome Multidrug Resistance in AML. A Mini Review
![Frontiers | Efficacy and safety of decitabine combined with HAAG (homoharringtonine, aclarubicin, low-dose cytarabine and G-CSF) for newly diagnosed acute myeloid leukemia Frontiers | Efficacy and safety of decitabine combined with HAAG (homoharringtonine, aclarubicin, low-dose cytarabine and G-CSF) for newly diagnosed acute myeloid leukemia](https://www.frontiersin.org/files/Articles/998884/fonc-12-998884-HTML-r1/image_m/fonc-12-998884-g001.jpg)
Frontiers | Efficacy and safety of decitabine combined with HAAG (homoharringtonine, aclarubicin, low-dose cytarabine and G-CSF) for newly diagnosed acute myeloid leukemia
![Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death | BMC Cancer | Full Text Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death | BMC Cancer | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12885-020-07701-8/MediaObjects/12885_2020_7701_Fig1_HTML.png)
Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death | BMC Cancer | Full Text
![Fernand Bteich on Twitter: Fernand Bteich on Twitter:](https://pbs.twimg.com/media/EpFi8rbXMAAhFe_.jpg)
Fernand Bteich on Twitter: "13/ Typical induction regimen is 7+3. Total is 7 days with 3 days of overlap. 7 days of cytarabine infusion. 3 days of anthracycline infusion (daunorubicin or idarubicin).
![Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients - ScienceDirect Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0923753419346460-gr1.jpg)
Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients - ScienceDirect
![Mathematical Models for the Influence of Cytarabine on White Blood Cell Dynamics in Acute Myeloid Leukemia | bioRxiv Mathematical Models for the Influence of Cytarabine on White Blood Cell Dynamics in Acute Myeloid Leukemia | bioRxiv](https://www.biorxiv.org/content/biorxiv/early/2018/09/27/428326/F1.large.jpg)
Mathematical Models for the Influence of Cytarabine on White Blood Cell Dynamics in Acute Myeloid Leukemia | bioRxiv
![Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial - The Lancet Haematology Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial - The Lancet Haematology](https://www.thelancet.com/cms/attachment/a29bdb5a-d820-4340-a9ee-aad2751e2b3d/gr1_lrg.gif)
Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial - The Lancet Haematology
![Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death | BMC Cancer | Full Text Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death | BMC Cancer | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12885-020-07701-8/MediaObjects/12885_2020_7701_Fig4_HTML.png)
Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death | BMC Cancer | Full Text
![Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia—a phase 3 study | Leukemia Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia—a phase 3 study | Leukemia](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41375-018-0268-9/MediaObjects/41375_2018_268_Fig1_HTML.png)
Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia—a phase 3 study | Leukemia
![Chemotherapy dosing schedule. The schedule for ARA-C (200 mg/m 2 /d),... | Download Scientific Diagram Chemotherapy dosing schedule. The schedule for ARA-C (200 mg/m 2 /d),... | Download Scientific Diagram](https://www.researchgate.net/publication/8451537/figure/fig1/AS:341207357116424@1458361581940/Chemotherapy-dosing-schedule-The-schedule-for-ARA-C-200-mg-m-2-d-daunorubicin-50.png)
Chemotherapy dosing schedule. The schedule for ARA-C (200 mg/m 2 /d),... | Download Scientific Diagram
![Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death | BMC Cancer | Full Text Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death | BMC Cancer | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12885-020-07701-8/MediaObjects/12885_2020_7701_Fig6_HTML.png)